With President Obama’s announcement in February 2013 that the United States will be launching trade negotiations with the European Union (“EU”) this summer, the pressure is on for Canada and the EU to complete the Canada European Union Comprehensive Economic and Trade Agreement (“CETA”) negotiations. Both Parties are said to be engaged in intense negotiations. [...]
With President Obama’s announcement in February 2013 that the United States will be launching trade negotiations with the European Union (“EU”) this summer, the pressure is on for Canada and the EU to complete the Canada European Union Comprehensive Economic and Trade Agreement (“CETA”) negotiations. Both Parties are said to be engaged in intense negotiations. Political choices may be inevitable in an agreement of this size and complexity.
This bulletin highlights five key areas of ongoing negotiations with significant implications for Canadian businesses: government procurement, financial services, investor protection, IP for pharmaceuticals, and rules of origin. We address strategic considerations.
American Association of Exporters and Importers (AAEI) Seminar Date: Wednesday, March 20, 2013 Location: Arent Fox | 1717 K St. NW | Washington, DC Panel Topics include: • OGA Trusted Trader Programs • Food and Drug Safety and Innovation Act • Pharmaceuticals, Health & Chemicals Center for Excellence & Expertise • U.S.-EU Mutual Recognition Agreement [...]
American Association of Exporters and Importers (AAEI) Seminar
Date: Wednesday, March 20, 2013
Location: Arent Fox | 1717 K St. NW | Washington, DC
Panel Topics include:
• OGA Trusted Trader Programs
• Food and Drug Safety and Innovation Act
• Pharmaceuticals, Health & Chemicals Center for Excellence & Expertise
• U.S.-EU Mutual Recognition Agreement and Impact on Admissibility
• PIC vs. ITDS vs International Standards
Keynote Speaker:
Deborah M. Autor, Esq.
Deputy Commissioner, Global Regulatory Operations and Policy
Food and Drug Administration
Registration Early Bird Prices: Member- $150 | Non-Member- $225
For more information go here.
GlaxoSmithKline prevailed in a tax challenge from the Canadian government. The U.K.-based drugmaker won backing from the country’s highest court, in a much-watched battle over using transfer pricing to cut its tax bill. At issue in the case were active-ingredient purchases made by Glaxo’s Canadian subsidiary between 1990 and 1993. The unit bought an API [...]
GlaxoSmithKline prevailed in a tax challenge from the Canadian government. The U.K.-based drugmaker won backing from the country’s highest court, in a much-watched battle over using transfer pricing to cut its tax bill.
At issue in the case were active-ingredient purchases made by Glaxo’s Canadian subsidiary between 1990 and 1993. The unit bought an API from a Swiss affiliate for 10 times the cost and 5 times the maximum paid by two other generics makers, Reuters reports. Canada’s Supreme Court ruled that the pricing was appropriate because of other benefits conferred by the Canadian unit’s licensing deal with GSK.
Transfer pricing has come under scrutiny in recent years, along with other methods big companies use to minimize their tax liabilities. Multinationals have been using intracompany billing to shift profits from one taxing jurisdiction to another for years. It’s legal, but as Reuters points out, taxing authorities often go after companies with aggressive pricing strategies.
Click here to read the Reuters news article.
Source: Tracy Staton | Fierce Pharma
(World Trade Interactive) According to the National Institute of Standards and Technology, the World Trade Organization has been notified of regulatory changes that may affect exports of specific products and services to the following countries… Canada: Prescription status of medicinal ingredients for human use (comments due by Sept. 13). Read more here.
(World Trade Interactive)
According to the National Institute of Standards and Technology, the World Trade Organization has been notified of regulatory changes that may affect exports of specific products and services to the following countries…
Canada: Prescription status of medicinal ingredients for human use (comments due by Sept. 13).
Read more here.
